Josh Bliesath Selected Research

CX 3543

10/2009

Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Josh Bliesath Research Topics

Disease

5	Neoplasms (Cancer) 07/2012 - 10/2009
1	Hypoxia (Hypoxemia) 12/2010
1	Carcinogenesis 10/2009
1	Carcinoid Tumor (Carcinoid) 10/2009
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2009

Drug/Important Bio-Agent (IBA)

2	RNA Polymerase I (Polymerase I, RNA)IBA 07/2012 - 02/2011
2	Carboxylic AcidsIBA 07/2012 - 01/2011
2	CX 5461IBA 07/2012 - 02/2011
2	Ribosomal DNA (rDNA)IBA 07/2012 - 10/2009
2	Pharmaceutical PreparationsIBA 07/2012 - 01/2011
2	silmitasertibIBA 01/2011 - 12/2010
1	benzo(c)fluoreneIBA 07/2012
1	EnzymesIBA 07/2012
1	RNA (Ribonucleic Acid)IBA 07/2012
1	Ribosomal RNAIBA 02/2011
1	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 02/2011
1	Casein Kinase II (Casein Kinase 2)IBA 01/2011
1	Adenosine Triphosphate (ATP)IBA 01/2011
1	Biological ProductsIBA 01/2011
1	CX 3543IBA 10/2009
1	Proteins (Proteins, Gene)FDA Link 10/2009
1	Phosphotransferases (Kinase)IBA 10/2009
1	NucleolinIBA 10/2009

Therapy/Procedure

1	Therapeutics 07/2012